Janux Therapeutics (JANX) Change in Accured Expenses (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Change in Accured Expenses data on file, last reported at -$2.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$2.0 million, down 217.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (down 67.33% YoY), and the FY2025 annual result was $6.3 million, up 42.11% from the prior year.
• Change in Accured Expenses grew to -$2.0 million in Q1 2026 per JANX's latest filing, from -$4.5 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $6.2 million in Q3 2025 and troughed at -$4.5 million in Q4 2025.
• A 5-year average of $715529.4 and a median of $1.0 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 605.87% in 2022, then tumbled 483.57% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $1.0 million in 2022, then sank by 57.61% to $426000.0 in 2023, then plunged by 483.57% to -$1.6 million in 2024, then sank by 176.38% to -$4.5 million in 2025, then jumped by 55.05% to -$2.0 million in 2026.
• Business Quant data shows JANX's Change in Accured Expenses at -$2.0 million in Q1 2026, -$4.5 million in Q4 2025, and $6.2 million in Q3 2025.